Live Breaking News & Updates on Oday Announced The Appointment Of Dr Feng Ren Asa Co Ceo Is Currently Insilico Medicine 39s Chief Scientific Officer And Head Global Research Development He Will Retain Those Titles Following Also Oversee Clinical With Full Control Over Discovery

Dr. Feng Ren, Chief Scientific Officer (CSO) and head of global research and development is named co-CEO of Insilico Medicine Highlights: Insilico Medicine is a global, end-to-end, fully-integrated AI-powered biotechnology company with three business models: AI platform, collaboration, and internal pipeline. It utilizes AI and a fully distributed, highly parallel discovery model to rapidly develop its own drugs. Since 2021, the company has nominated 8 preclinical candidates and reached Phase I clinical trials with an AI-discovered and AI-designed molecule. It is also developing a set of AI platforms for target discovery, multi-parameter optimization, generative chemistry, and prediction of clinical trials. In the pharmaceutical industry, the internal pipeline, and especially, clinical assets, are much more important and expensive than computational platforms and other enabling technologies. Historically, companies in computationally-augmented discovery, reduced or completely eliminated ....

Feng Ren , United States , Alex Zhavoronkov , Harvard University , Head Of Global Research , Chief Scientific Officer , Powered Drug Discovery , Insilico Medicine , Global Research , Senior Vice President , Dr Feng Ren , Hief Scientific Officer Cso And Head Of Global Research Development Is Named Co Ceo Insilico Medicine Highlights Isa , Nd To End , Ully Integrated Ai Powered Biotechnology Company With Three Business Models Platform , Nd Internal Pipeline It Utilizes Ai Anda Fully Distributed , Ighly Parallel Discovery Model To Rapidly Develop Its Own Drugs Since 2021 , He Company Has Nominated 8 Preclinical Candidates And Reached Phasei Clinical Trials With An Ai Discovered Designed Molecule It Is Also Developinga Set Of Platforms For Target Discovery , Ulti Parameter Optimization , Generative Chemistry , Nd Prediction Of Clinical Trials In The Pharmaceutical Industry , He Internal Pipeline , End Especially , Clinical Assets , Re Much More Important And Expensive Than Computational Platforms Other Enabling Technologies Historically , Ompanies In Computationally Augmented Discovery , Educed Or Completely Eliminated The Teams Developing Platforms In Favor Of Pipeline Assets Insilico Will Ensure Continued Leadership Its Ai And Robotics Platform Technology Focus On Internal Partnered Therapeutic ,